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Summary Endogenous opioid peptides have been shown to be involved in the regulation of tumour growth.
At present, however, no data are available about the secretion of opioid peptides in cancer patients.
To draw some preliminary conclusions on opioid brain function in human neoplasms, we evaluated
hypophyseal hormone responses to the administration of a met-enkephalin analogue, FK33-824. The study
included 14 patients affected by early or advanced neoplastic disease, 12 healthy subjects and 7 patients with a
chronic medical illness other than cancer.
FK33-824 was given intravenously at a dose of 0.3 mg. Venous blood samples were collected at zero time,
and 30, 60 and 120min after drug administration. In each sample, PRL, GH, LH, cortisol and ,B-endorphin
levels were measured by RIA.
In all normal subjects and in patients with non-neoplastic chronic illness, FK33-824 induced a rise in PRL
and GH levels, and a decrease in LH, cortisol and ,B-endorphin. A normal endocrine response to FK 33-824
was seen in one cancer patient only, while in the other cases with tumour no hormonal changes or a
paradoxical response were seen after FK33-824.
Based on the fact that an abnormal endocrine response to FK33-824 has been described in hypothalamic-
pituitary disorders, in which anomalous brain opioid activity has been demonstrated, these results suggest the
existence of an altered function of the opioid system in cancer patients, the clinical importance of which
remains to be determined.
There is mounting evidence indicating that endogenous
opiates play a critical part in the control of immune
functions (Weber & Pert, 1984). Moreover, recent experi-
mental observations seem to demonstrate an involvement of
endogenous opioid peptides in the regulation of tumour
growth. As regards this hypothesis, however, the results are
contradictory, since opioid substances have been seen to
exert either a stimulatory (Lewis et al., 1983a, b; Simon et
al., 1984) or an inhibitory role (Plotnikoff & Miller, 1983) on
tumour growth, depending on the different experimental
conditions. Opioid antagonists may also have stimulatory
and inhibitory effects, depending on the dosage (Zagon &
McLaughlin, 1983).
As far as the evaluation of endogenous opioid secretion in
cancer patients is concerned, no data are yet available.
Preliminary results would seem to suggest an anomalous
fJ-endorphin circadian rhythm in human neoplasms (Lissoni
et al., 1986), the clinical significance of which remains to be
determined.
To further elucidate the nature of the opioid activity in
human cancer, we studied the effects of a met-enkephalin
analogue on the release of hypophyseal hormones in a group
of patients suffering from early or advanced neoplastic
disease.
Materials and methods
The study was carried out on 14 patients of both sexes (5
men, 4 premenopausal and 5 postmenopausal women), aged
between 32 and 53 years (mean age 46.4 years), with
histologically proven neoplastic disease. Patients were
followed in the outpatient clinic of San Gerardo Hospital,
Monza. Diagnosis of cancer was made for at least 4 months
prior to study (4 months-5 years; mean 3.8 years). Breast
cancer and lung carcinoma were the two neoplasms most
frequently represented in our cases. Chronic pain was
present in 2 patients only. Clinical data of cancer patients
are given in Table I.
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As controls, 12 healthy volunteers (6 men, 4 premeno-
pausal and 2 postmenopausal women) of same age (28-51
yrs; mean 42.4) were included in the study. Volunteers were
from among hospital attendants. Moreover, a second group,
consisting of 7 patients (4 men, 2 premenopausal and one
postmenopausal women), aged between 31 and 58 years
(mean 49.3), affected by a chronic medical illness other than
cancer, was evaluated. None of the patients was hospitalized
during the study. The experimental protocol was explained
to patients and volunteers, and informed consent was
obtained.
None of the cancer patients had been previously treated
with oestrogens, antioestrogens or glucocorticoids. No anti-
emetics or other psychotropic drugs were given for at least
one week prior to study. Moreover, no patient received
opiates to relieve pain; finally, patients who received chemo-
therapy were observed for at least 20 days after the last
administration ofcytotoxic drugs.
All procedures were begun at 9.00 after an overnight fast
during the summer season. FK33-824 (DAMME; Sandoz,
Basel, Switzerland), a longer-acting met-enkephalin analogue,
was administered i.v. at a dose of 0.3mg in 10ml of saline
solution over 5min. Venous blood samples were drawn
through an indwelling catheter at zero time, and 30, 60 and
120min after FK33-824 infusion. On a separate occasion
and after an interval of at least one week, the healthy
subjects were studied during a saline infusion only.
In each venous sample, serum levels of PRL, GH, LH,
cortisol, and plasma concentrations of ,B-endorphin were
measured. Sera and plasma were obtained by centrifugation,
and stored at -20°C until assayed. Hormonal assays were
made within 10 days after blood sampling. PRL, GH, LH
and cortisol serum levels were measured by RIA using
commercial available kits (Sclavo, Milan, Italy), while
plasma values of f,-endorphin were detected with the
commercial kits developed by Nichols Institute Diagnostics
(San Juan Capistrano, California). All samples were assayed
in duplicate in a single assay. the intraassay and interassay
coefficients of variation were below 6% and 9%,
respectively.
Statistical analyses were performed by Student's t test and
analysis of variance according to the Newman Keuls test and
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Table I Clinical data
Age Body Site of Performance Chronic Previous
Cases Sex (yrs) weight (kg) Tumour TNM metastases statusa pain treatmentb
1 M 51 77 Squamous cell lung T3N2MO 70 - RT+CDDP
2 M 48 82 Squamous cell lung T3N2M1 Brain 90 -
3 F 46 69 Squamous cell lung T2N2MO 80 - RT+CDDP-VP16
4 M 53 71 Small cell lung T3N2MO 60 - RT+CDD-VP16
5 F 50 68 Small cell lung T3N2M1 Nodes, bone 40 + CEV
6 F 46 79 Breast TxNxM1 Bone 60 - Surgery
7 F 32 49 Breast T4N3M1 Liver 20 FEC
8 F 48 67 Breast T2N1M1 Skin, bone, lung 40 + FEC
9 F 42 63 Breast T2N1MO 100 - Surgery+CMF
10 F 38 59 Breast T2N1Mo 100 - Surgery+CMF
11 M 51 68 Gastric TxNxM1 Liver 70 - Surgery+5-FU
12 M 53 73 Thymoma 80 -
13 F 42 62 Uterine cervix T3N1MO 100 - CDDP
14 F 49 83 Uterine cervix T3N1MO 90 - CDDP
aKamofsky; bRT: Radiotherapy; CDDP: Cis-platinum; VP,,: Etoposide; CEV: Cyclophosphamide, Epirubicin, Vincristine; FEC:
Fluorouracil, Epirubicin, Cyclophosphamide; CMF: Cyclophosphamide, Methotrexate, Fluorouracil; 5-FU: Fluorouracil.
adjusted for a correction factor. Results were reported as the
mean+s.e. Hormonal basal levels were considered as 'high'
or 'low' when they were greater or less than 2 s.d. relative to
those observed in healthy subjects.
Results
All patients and healthy subjects experienced an unpleasant
feeling of heaviness of the body, particularly in the legs, of a
few minutes' duration only, associated with a facial flushing
and headache in some cases. No change in pulse or blood
pressure was observed.
Figures 1 and 2 illustrate blood levels (mean+s.e.) of PRL
and GH, respectively, observed in healthy subjects, cancer
patients and those with chronic illness other than cancer.
In all healthy volunteers and in patients with chronic
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disease other than cancer, increases of PRL (>200%) and of
GH (>lOpgml-1) were seen after FK33-824, with a peak
at 30min. LH, cortisol and fl-endorphin decreased after
FK33-824, with a fall >50% in respect to their basal values.
The lowest levels of LH and f,-endorphin were found at
60min and those of cortisol after 120min. In the healthy
volunteers, PRL and GH serum mean levels observed at 30
and 60min after FK33-824 were significantly higher than
both those seen during saline infusion at the same times and
those found in basal conditions (P<0.001). Cortisol and
/3-endorphin mean values were significantly lower (P<0.005)
after FK33-824 than during saline at 120 and 60min,
respectively. Moreover, LH mean values were significantly
lower at 30, 60 and 120min after FK33-824 than during
saline and at their basal levels (P<0.001). Finally, no
significant differences were seen between healthy subjects
30
Time (minutes)
Figure 1 PRL serum mean levels after FK 33-824 in healthy
subjects (0 0; n = 12) and in patients with neoplastic
(A \A; n= 14) and non-neoplastic (O 0; n=7) disease.
* p <0.001 vs. cancer patients
** p <0.01 vs. cancer patients
*** p <0.05 vs. cancer patients
0 30 60 120
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Figure 2 GH serum mean levels after FK 33-824 in healthy
subjects (0 *; n = 12) and in patients with neoplastic
(A /A; n = 14) and non-neoplastic (0 0; n=7) disease.
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and patients with chronic disease other than cancer in any of
the hormone levels after administration of FK33-824.
Among cancer patients, a normal increase of GH and
PRL after FK33-824 was seen in only 3/14 patients (21%).
The peak, however, was delayed. In 2 patients with high GH
basal levels, a paradoxical fall in the level of hormone was
seen after FK 33-824. In all other cases both GH and PRL
were not affected by the met-enkephalin analogue. LH values
showed a decrease in excess of 50% after FK33-824 in one
cancer patient only. Finally, a normal fall in cortisol and
fl-endorphin levels was seen in 8/14 and in 9/14 patients,
respectively, while the levels increased after FK33-824 in 3
and 2 cases, respectively.
No significant difference was seen in cancer patients in
GH, PRL and LH mean serum levels at any single point of
the curve in response to FK33-824 in respect of their basal
values. Cortisol and .B-endorphin mean concentrations were
significantly lower at 120min (P<0.05) and at 60min
(P<0.05), respectively, than basal values.
PRL mean levels observed in normal subjects were
significantly higher than in cancer patients at 30min
(P<0.005) and at 60min (P<0.05) after FK33-824. GH
mean values were significantly higher in the normal subjects
than in cancer patients at 30min (P<0.001) and at 60min
(P<0.01). PRL and GH mean levels were also significantly
higher in patients with non-neoplastic chronic illness than in
cancer patients at 30min (P<0.025 and P<0.05,
respectively) after the administration of FK33-824. In
contrast, no significant difference was seen in mean levels of
cortisol and /-endorphin between cancer patients and normal
subject or patients with non-neoplastic chronic disease.
Discussion
According to data previously reported (Stubbs et al., 1978),
the met-enkephalin analogue induces an increase in PRL and
GH, and a fall in LH and cortisol levels in normal subjects.
Moreover, similar hormone behaviour was seen in patients
suffering from chronic medical illnesses other than cancer.
Hypophyseal hormonal responses to FK33-824 would
depend on the endogenous brain opioid tone; infact, an
altered response to FK33-824 has been described in several
hypophyseal-hypothalamic and/or suprahypothalamic
disorders (De Leo et al., 1985), which are characterized by
anomalous opioid activity (Quigley et al., 1980a,b). There-
fore, the results of the present study, by showing altered
hypophyseal response to the administration of a met-
enkephalin analogue in cancer patients, provide indirect
evidence of an altered function of the opioid system in
human neoplasms; in particular, PRL and GH responses
appear to be altered. Alternatively, the abnormal endocrine
responses to FK33-824 observed in cancer could depend on
different pharmacokinetics of the met-enkephalin analogue.
The altered hormone response to opioid stimulation in
cancer patients, however, does no seem to be simply a
consequence of the stress of illness, since no abnormal
endocrine pattern was observed in patients suffering from
chronic non-neoplastic disease after FK33-824 admin-
istration. Moreover, the altered response to the met-
enkephalin analogue would depend neither on the
histological type of tumour, nor on the clinical stage because
of the anomalous endocrine patterns observed in different
types of tumour, both in patients with early and advanced
neoplastic disease. Finally, the abnormal response to the
opioid agonist was related neither to the chemotherapy, nor
the duration ofneoplastic disease.
The investigation of pituitary responsiveness to opioid
stimulation can allow us to further elucidate the status of the
psychoneuroendocrine system in cancer patients, in whom
several neuroendocrine anomalies have been reported,
including an exaggerated response of PRL to TRH in breast
cancer (Willis et al., 1977; Barni et al., 1986a), as well as a
paradoxical response of GH to TRH (Barni et al., 1986b),
reduced LH secretion after GnRH in Hodgkin's disease
(Viviani et al., 1985), and abnormally high (Raikhlin et al.,
1980) or low (Pico et al., 1979) melatonin levels in various
types of tumour. Because of the importance of endogenous
opioid peptides in modulating neuroendocrine functions, it
may be hypothesized that the anomalous endocrine
responses observed in cancer patients are due to altered
brain opioid activity. Moreover, on the basis of the well
documented role played by opioid peptides in the regulation
of immunity (Weber & Pert, 1984) and tumour growth
(Lewis et al., 1983a,b; Zagon & McLaughlin, 1983) it is
possible that the altered function of the opioid system may
be of prognostic significance. At present, however, it is not
possible to establish if the opioid dysfunction precedes or
succeeds tumour development.
Further studies, conducted on a larger sample to evaluate
the effects of both opioid agonists and antagonists, are
required to investigate opioid function in human cancer and
its influence on clinical course. A more detailed knowledge
of opioid function in cancer patients could, in future,
constitute a basis for a neuroendocrine therapeutic approach,
in association with standard antitumour therapies.
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